{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:36:36Z","timestamp":1785306996800,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Minoxidil and the 5\u2010alpha reductase inhibitors (5\u2010ARIs), specifically, dutasteride and finasteride, are usually used to treat pattern hair loss (PHL), but evidence on the relative effectiveness of these drugs is far less for women than men.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>We performed an age\u2010adjusted network meta\u2010analysis (NMA) to determine the comparative efficacy of monotherapy with the three agents\u2014in any dosage and administrative route\u2014on PHL in adult women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The peer\u2010reviewed literature was systematically reviewed to obtain data for our NMA. The outcome measure for our NMA was \u201cchange in total hair density.\u201d We referred to \u201cregimen\u201d as an \u201cagent and its dosage;\u201d our Bayesian NMA estimated regimens' surface under the cumulative ranking curve (SUCRA) values and pairwise relative effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our NMA used data from 13 trials\u2014across which the following 10 regimens were identified (in decreasing order of SUCRA): 5\u2009mg\/day finasteride for 24\u2009weeks (SUCRA\u2009=\u200995.7%), 5% topical minoxidil solution twice daily for 24\u2009weeks (SUCRA\u2009=\u200989.5%), 1\u2009mg\/day minoxidil for 24\u2009weeks (SUCRA\u2009=\u200978.1%), 5% topical minoxidil foam 1 half capful\/day for 24\u2009weeks (SUCRA\u2009=\u200966.5%), 3% topical minoxidil solution 1\u2009mL twice daily for 24\u2009weeks (SUCRA\u2009=\u200945.1%), 2% topical minoxidil solution 1\u2009mL twice daily for 24\u2009weeks (SUCRA\u2009=\u200944.6%), 5% topical minoxidil solution 1\u2009mL\/day for 24\u2009weeks (SUCRA\u2009=\u200941.7%), 0.25\u2009mg\/day minoxidil for 24\u2009weeks (SUCRA\u2009=\u200935.5%), 1.25\u2009mg\/day finasteride for 24\u2009weeks (SUCRA\u2009=\u200924.8%) and 1\u2009mg\/day finasteride for 24\u2009weeks (SUCRA\u2009=\u20094.3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings can improve clinical guidelines and help dermatologists manage female PHL more optimally with the available options.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.15910","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T06:04:14Z","timestamp":1688105054000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The relative effect of monotherapy with 5\u2010alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta\u2010analysis study"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"},{"name":"Division of Dermatology, Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Bamimore","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0691-640X","authenticated-orcid":false,"given":"Mesbah","family":"Talukder","sequence":"additional","affiliation":[{"name":"School of Pharmacy BRAC University  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.88a.20014"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5743"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.01.008"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_2_13_6_1","unstructured":"Posit team.RStudio: Integrated Development Environment for R 2022."},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/rssa.12579"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2020.04.012"},{"issue":"7","key":"e_1_2_13_10_1","first-page":"874","article-title":"A phase III, multicenter, parallel\u2010design clinical trial to compare the efficacy and safety of 5% minoxidil foam versus vehicle in women with female pattern hair loss","volume":"15","author":"Bergfeld W","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06295.x"},{"issue":"7","key":"e_1_2_13_12_1","first-page":"883","article-title":"Efficacy and safety of once\u2010daily minoxidil foam 5% versus twice\u2010daily Minoxidil solution 2% in female pattern hair loss: a phase III, randomized, investigator\u2010blinded study","volume":"15","author":"Blume\u2010Peytavi U","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.01.017"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13228"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2012.24.3.370"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.905140"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-020-03157-1"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107953"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0387-0"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15131"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03758.x"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.1448"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543400903105406"},{"key":"e_1_2_13_24_1","volume-title":"Classification and Scoring of Androgenetic Alopecia (Male and Female Pattern)","author":"Firooz A","year":"2019"},{"key":"e_1_2_13_25_1","unstructured":"European Medicines Agency; list of nationally authorised medicinal products (active substance: finasteride) 2022;https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/finasteride\u2010list\u2010nationally\u2010authorised\u2010medicinal\u2010products\u2010psusa\/00001392\/202108_en.pdf"},{"issue":"9","key":"e_1_2_13_26_1","first-page":"S31","article-title":"Comparison of clinical trials with finasteride and dutasteride","volume":"6","author":"Nickel JC","year":"2004","journal-title":"Rev Urol"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.15910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T01:36:34Z","timestamp":1707442594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.15910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/jocd.15910"],"URL":"https:\/\/doi.org\/10.1111\/jocd.15910","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"2023-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}